Type 1 diabetes: real-world effectiveness of insulin glargine 300 units/mL across the UK

  • Pang T & al.
  • Diabet Med
  • 25 Oct 2018

  • curated by Sarfaroj Khan
  • UK Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.


  • In a population with type 1 diabetes representative of clinical practice in the United Kingdom, a change in basal insulin to insulin glargine 300 units/mL (U300) was associated with statistically significant and clinically meaningful reduction in HbA1c, without significant changes in basal insulin dose and weight.

Why this matters

  • The use of U300 in people with type 1 diabetes mellitus is supported by results from 2 phase 3, randomised, controlled trials; however, no participants from the United Kingdom were included in these trials, and no real-world evidence exists regarding the use of U300 in type 1 diabetes in the UK clinical practice.

Study design

  • This retrospective, observational, single-arm study included patients with type 1 diabetes (n=298; mean age, 42.1 years; mean HbA1c, 79 mmol/mol [9.4%]) who were prescribed their first dose of U300 ≥6 months before data collection (August 2015) and had HbA1c results within 3 months before starting U300.
  • Primary outcome included change in HbA1c from baseline to month 6 after U300 initiation.
  • Funding: Sanofi UK.

Key results

  • HbA1c significantly reduced from baseline [78 mmol/mol (9.3%)] to month 6 post initiation of U300 [74 mmol/mol (8.9%)], with a mean difference of −4 mmol/mol (–0.4%; P<.001 n="188).</li">
  • Significant increase in basal insulin dose of 1.3 units from U300 initiation to 6 months was observed (P<.001 n="275).</li">
  • No clinically significant difference in weight between baseline and month 6 was reported (mean difference, +0.7 kg; P=.084; n=115).
  • Documented severe hypoglycaemic episodes were experienced by 6/298 and 4/298 participants during the 6 months before and after U300 initiation, respectively.
  • Ketoacidosis episodes requiring Accident and Emergency department visits or hospitalisation were documented in 4/298 and 6/298 participants, before and after U300 initiation, respectively.


  • Observational design.